Tanya B. Dorff, MD, presented “mHSPC: Latest Approaches and Clinical Trials” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Dorff, Tanya B. “mHSPC: Latest Approaches and Clinical Trials.” February 9, 2025. Accessed Jul 2025. https://grandroundsinurology.com/mhspc-latest-approaches-and-clinical-trials/
mHSPC: Latest Approaches and Clinical Trials – Summary
Tanya B. Dorff, MD, City of Hope, Duarte, California, explores the evolving treatment landscape for metastatic hormone-sensitive prostate cancer. In this 15-minute presentation, Dr. Dorf emphasizes the role of doublet and triplet therapies.
Dr. Dorff highlights the survival benefits of androgen receptor pathway inhibitors and raises questions about the additional value of docetaxel in triplet regimens. She emphasizes tailoring treatment based on individual patient factors such as comorbidities, life expectancy, and concurrent medications rather than relying on a universal approach.
She indicates that biomarker-driven strategies, such as decipher scoring, are gaining traction. Recent data shows improved outcomes with triplet therapy, especially in high-volume cases, but more evidence is needed to define its exact role. She also shares that lutetium PSMA therapy’s potential benefit in earlier disease stages is also being explored with cautious optimism.
Continued research into molecular stratification, treatment de-intensification, and rational sequencing strategies are crucial for improving outcomes. The importance of continued research into molecular stratification, treatment de-intensification, and rational sequencing strategies is emphasized as key to improving outcomes in this patient population.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Tanya B. Dorff, MD, serves as an Associate Clinical Professor in the Department of Medical Oncology & Therapeutics Research and as the Head of the Genitourinary Cancers Program at City of Hope, a research and treatment center for cancer based in Duarte, California.
Dr. Dorff completed her BS degree at the University of Houston before attending the University of California, Los Angeles School of Medicine. She then completed her internal medicine residency at Mt. Sinai Hospital in New York, and finished subspecialty training in hematology and oncology at Los Angeles County + University of Southern California (USC) Medical Center. Following her training, Dr. Dorff remained on the faculty at USC. She has been published in over 70 publications, including in top-tier journals like Cancer, Lancet Oncology, and Journal of Clinical Oncology. She has been invited to speak at multiple national and international meetings, and serves on the American Society of Clinical Oncology Scientific Committee and the National Cancer Institute Prostate Cancer Task Force.
Dr. Dorff’s research interests in prostate cancer range from clinical trials in PSA-recurrent prostate cancer to the role of fasting in chemotherapy tolerability to CAR T-cells that are primed to target prostate cancer tissue.
